GMP Regulatory News & NHS Aseptic Services | Edition 27
GMP update covering pharmaceutical quality news, regulator developments, global recalls, NHS aseptic services and practical audit readiness.
GXP COMPLIANCE NEWSLETTER
Kyle Winn and Adam Walker
1/12/20267 min read
Introduction
As we step into a new year, I (Kyle Winn) and Adam Walker want to start by saying thank you! You are the reason this newsletter exists.
Our focus in 2026 is simple: keep delivering practical, inspection-ready GMP content through this newsletter, and keep publishing free education on the Help Me GxP YouTube channel so anyone in manufacturing, aseptics, quality, QC, QA, and supply chain can build confidence and competence without paywalls.
We will be honest: sometimes work and life get in the way. Both of us balance demanding day jobs alongside Help Me GMP, and this project is built in the margins. But we are committed to consistency, and we are actively looking at ways to improve our capacity so we can support you better, release content more reliably, and keep raising the quality of what we share.
If you are new here, welcome. If you have been with us for a while, thank you for sticking with us. Either way, our goal remains the same: make GMP clearer, more practical, and easier to apply when it matters most.
From the Help Me GMP YouTube Channel
We also want to share a quick snapshot of what the community has been engaging with recently on the Help Me GMP YouTube channel.
Last week we published our latest video:
What Is a QMS in Pharma? https://youtu.be/hihjuH93T48
This video breaks down what a Quality Management System actually is in a pharmaceutical context, how it fits together, and why inspectors care less about documents in isolation and more about how the system functions as a whole. Early engagement has been strong, with positive feedback on clarity and practicality, and we are currently running A/B testing to continue improving reach and accessibility.
Alongside this, one of our cornerstone videos has just passed a major milestone:
What Is GMP? https://youtu.be/Pr_A0lcL5Ow
This video has now exceeded 2,000 views and received 52 likes, making it one of the most-watched pieces of content we have produced to date. For a fundamentals topic, this level of engagement reinforces what many of you tell us directly: there is still a real need for clear, plain-spoken explanations of GMP that go beyond acronyms and regulatory jargon.
We will continue to build on this foundation throughout 2026, focusing on core GMP topics, real inspection expectations, and practical examples that teams can actually apply on the shop floor, in aseptic units, and within quality systems.
News in Pharma – Last 14 Days
1. UK regulator approves a new cancer treatment The MHRA has approved Nirogacestat hydrobromide for the treatment of desmoid tumours, marking a new licensed oncology medicine in the UK regulatory landscape. This decision reflects the continued expansion of targeted cancer therapies in Europe.
https://www.gov.uk/government/news/mhra-approves-nirogacestat-for-desmoid-tumours-7-january-2026
2. MHRA leadership and vaccine approval updates The MHRA announced Professor Jacob George as its new Chief Medical and Scientific Officer and also approved a COVID-19 vaccine (zapomeran) in early January 2026. These organisational and regulatory actions illustrate ongoing updates within the UK regulator’s scientific leadership and vaccine authorisation activities.
https://www.gov.uk/government/news/mhra-welcomes-new-chief-medical-and-scientific-officer
3. Independent vaccine evidence review following HPV recommendation change An independent expert group will review HPV vaccine evidence after changes in U.S. recommendations that altered the dosage schedule. While not a regulatory decision itself, this review response will impact future immunisation strategy discussions.
4. Healthcare M&A sentiment grows ahead of J.P. Morgan Conference Newswire reporting from Reuters highlights that healthcare dealmakers are gathering with expectations of renewed large mergers and acquisitions in 2026, indicating industry strategic realignment in response to patent expiries and pricing pressures.
5. MHRA Drug Safety Update on strengthened warnings The MHRA published its January 2026 Drug Safety Update, advising clinicians about strengthened warnings for medications including benzodiazepines, pregabalin, and gabapentin due to risks of addiction, dependence and withdrawal. This has direct implications for prescribing practice and product information requirements.
https://www.prescriber.org.uk/2026/01/drug-safety-update-january-2026/
Recalls In Pharma
1. EU (Ireland – HPRA)
Palmeux 20 mg powder for concentrate for solution for infusion Action: Batch recall Authority: Health Products Regulatory Authority (HPRA) Date published: Early January 2026
The HPRA issued a recall for Palmeux 20 mg powder for infusion following GMP concerns identified at the manufacturing site. The recall is precautionary and relates to assurance of GMP compliance rather than confirmed patient harm. This type of action demonstrates how upstream GMP deficiencies can trigger immediate market actions across the EU supply chain, even where clinical risk has not yet materialised.
2. USA (FDA)
ReBoost Nasal Spray and ClearLife Allergy Nasal Spray Action: Voluntary nationwide recall Authority: US Food and Drug Administration (FDA) Date posted: Mid–December 2025
MediNatura New Mexico Inc. expanded a voluntary recall after testing identified microbial contamination, including yeast, mould, and Achromobacter species above acceptable limits. The FDA noted a potential risk of serious infection, particularly in immunocompromised patients. Although not sterile injectables, this recall reinforces the regulatory expectation that microbiological controls are risk-based and proportionate to patient exposure.
3. USA (FDA)
Multiple FDA-regulated drug products held by Gold Star Distribution Inc. Action: Recall due to insanitary distribution conditions Authority: US Food and Drug Administration (FDA) Date posted: Late December 2025
The FDA announced a recall covering drug products distributed from a single warehouse after inspections identified insanitary conditions, including pest contamination. This recall was driven by GDP and storage failures, not manufacturing defects. It highlights that GMP responsibility does not end at batch release; distribution controls are a critical part of product quality and patient safety.
4. UK (MHRA)
Prednisolone 5 mg Soluble Tablets Action: Class 3 Medicines Recall Authority: MHRA Date published: December 2025 (most recent UK medicines recall available)
The MHRA issued a Class 3 recall following reports of swollen blister pockets over time, which may affect tablet integrity. While patient harm is considered unlikely, the product does not fully meet quality specifications. This recall is a good reminder that packaging system performance is a GMP-critical attribute and must be supported by robust stability and compatibility data.
Link (MHRA alerts index): https://www.gov.uk/drug-device-alerts
5. UK (MHRA)
Clarithromycin 500 mg powder for concentrate for solution for infusion Action: Class 2 Medicines Recall Authority: MHRA Date published: December 2025
This recall followed concerns linked to supplier certification and GMP compliance, requiring quarantine and return of affected batches. Class 2 recalls indicate a potential risk to patients and typically attract close scrutiny of supplier oversight, batch certification, and quality agreements during inspection.
Link (MHRA alerts index): https://www.gov.uk/drug-device-alerts
Upcoming conferences and training
Pharmapack 2026 21 to 22 January 2026, Paris Expo Porte de Versailles, Paris Focus: Packaging, drug delivery systems, device and primary pack innovation, supply chain resilience. https://www.pharmapackeurope.com/en/home.html
PDA - Parenteral Drug Association Good Aseptic Manufacturing Conference 2026 11 to 12 June 2026, Frankfurt, Germany Focus: Annex 1 implementation, contamination control strategies, aseptic processing best practice, EM, APS, barrier technologies. https://www.pda.org/global-event-calendar/event-detail/pda-good-aseptic-manufacturing-conference-2026
ISPE Europe Annual Conference 2026 20 to 22 April 2026, Copenhagen, Denmark, and virtual Focus: Manufacturing strategy, quality systems, facility and equipment lifecycle, digital and compliance topics. https://ispe.org/conferences/2026-europe-annual-conference
Making Pharmaceuticals 2026 21 to 22 April 2026, Coventry Building Society Arena, Coventry, UK Focus: UK pharma manufacturing, supply chain, QA, regulation, and technology. https://www.makingpharma.com/
NHS Aseptic Services Updates
Checked against NHS Specialist Pharmacy Service content and current NHS assurance framework
Monthly iQAAPS Quality Indicator submissions remain mandatory
All NHS aseptic preparation services operating under Section 10 exemption are required to submit monthly Quality Indicator (QI) data via the iQAAPS system. This requirement remains live and is actively monitored by Specialist Pharmacy Service (SPS) QA teams.
QI data includes, but is not limited to: • Grade A environmental monitoring results • Aseptic Process Simulation outcomes • Errors, incidents, and trends • Audit actions and follow-up status
Failure to submit, late submission, or unexplained data anomalies are routinely escalated and can directly influence risk-based audit scheduling and regulatory attention.
Official SPS guidance page (correct landing page): https://www.sps.nhs.uk/articles/submitting-iqaaps-quality-indicators-qis/
SPS QA oversight and risk-based audit planning
SPS continues to operate a risk-based oversight model for NHS aseptic services. iQAAPS data, audit history, incident trends, staffing competence, and service complexity are all used to inform: • Audit frequency • Audit scope and depth • Escalation to NHS England where required
Units should not assume that a recent audit reduces scrutiny. Strong data submission, trend analysis, and documented management review remain critical between audits.
SPS aseptic services overview (authoritative page):
Practical SPS-aligned reminder for units
SPS inspectors and QA pharmacists are increasingly focused on how data is reviewed, not just whether it is submitted. Units should be able to clearly demonstrate: • Monthly QI review by appropriate senior staff • Documented actions arising from trends • Clear linkage between iQAAPS data, deviations, CAPAs, and management review
SPS Upcoming Aseptic-relevant Training & Learning Events
Understanding Objectionable Microorganisms (Webex) • Date: 21 January 2026, 13:00–14:00 (online via Webex) • Focus: SPS QA bite-size learning on what objectionable microorganisms are, why they matter in aseptic services, how to investigate them, and how to respond effectively in your contamination control strategy. This session emphasises practical microbiological risk understanding and response actions that link directly to quality systems, investigations and CAPA. Official SPS event page: https://www.sps.nhs.uk/articles/understanding-objectionable-microorganisms/
Updated Clinical Trials Regulation: Implementation Considerations • Date: 26 February 2026 • Focus: Learning event covering practical aspects of the updated clinical trials regulation, which has implications for aseptic units that handle IMPs (investigational medicinal products) under NHS aseptic practice. SPS “Next Events” listing: https://www.sps.nhs.uk/home/events/next-events/
Other broader NHS/SPS training that may be of interest but not strictly aseptic-only include: • Managing Medicines Inventory in Hospital Pharmacy – 4 February 2026 (procurement focus) • SMRs in Problematic Polypharmacy (Respiratory) – 13 January 2026 • SMRs in Problematic Polypharmacy (Diabetes) – 10 February 2026
Fun GMP Fact
The word “aseptic” does not mean sterile. It literally means “without infection”, and in GMP terms it describes a controlled process designed to prevent contamination, not eliminate it outright.
That distinction is why regulators focus so heavily on process control, behaviour, and contamination prevention, rather than simply relying on end-product testing. You cannot test quality into an aseptically prepared product. You have to build it in, step by step, every time.
Summary
If you find this newsletter useful, please share it with a colleague who works in manufacturing, aseptics, quality, QC, or QA. The more people who understand GMP properly, the safer and stronger our systems become.
Subscribe to the Help Me GMP YouTube channel for free, practical training that you can use on the job, whether you are new to GMP or years into your career. Every view, share, and comment helps us keep this content accessible and independent.
We will keep doing our best to show up consistently and deliver clear, inspection-ready GMP education. Thank you for being part of the Help Me GMP community.
Contact
Get in touch
info@w2cleanrooms.com
© 2026. All rights reserved.
Our Brands
Free GxP Training
